Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the safety and efficacy of paamprilimab
combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma. The primary
endpoint was pathological complete response rate (CPR).